Healthcare Global Enterprises Sees 11% Profit Dip Amid Growth Investments
Healthcare Global Enterprises reports an 11% dip in profit after tax, down to Rs 16 crore in Q2 of FY26, due to higher depreciation and interest from growth investments. Despite this, revenue increased by 17% to Rs 647 crore. The company focuses on advanced diagnostics and targeted therapies.
- Country:
- India
Cancer-focused healthcare provider, Healthcare Global Enterprises, reported an 11% decrease in profit after tax, reaching Rs 16 crore in the September quarter of FY26.
The Bengaluru-based company had recorded a Rs 18 crore profit in the same quarter last fiscal, citing higher depreciation and interest expenses from growth strategies and acquisitions.
Despite the dip in profit, the firm saw a 17% year-on-year increase in revenue, totaling Rs 647 crore for Q2. HCG is investing in advanced molecular diagnostics and organoid-based platforms to advance drug discovery tailored to Indian genetic diversity.
ALSO READ
-
ADB’s $1.3 Billion Mongolia Plan Backs Better Healthcare, Schools and Disaster Readiness
-
African Development Bank Steps Up Push to Deliver Roads, Airport and Services in CAR
-
ADB’s Five-Year Plan Backs Better Services and More Jobs Across Papua New Guinea
-
Philippines Could Unlock Billions Through Smarter Taxes and Public Spending
-
KSrelief and UNDP Launch $5M Lifeline for Ukraine’s War-Affected Hospitals
Google News